Low‐dose colchicine vs NSAIDs
Withdrawals due to adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
19 questions · 19 findings · 13 reviews
No studies found 4 · 21.1%GRADE not reported 2 · 10.5%Very low 7 · 36.8%Low 5 · 26.3%Moderate 1 · 5.3%High 0 · 0%
Low‐dose colchicine vs placebo
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 133 participantsGRADE not reported
Swallowed fluticasone vs prednisone
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
- RR 0.5 [0.16, 1.53]1 study · 80 participantsVery low
Uric acid lowering therapies (UAR) vs placebo
Withdrawals due to adverse events · hyperuricaemia in people with hypertension
Uric acid‐lowering drug showed no clear difference in adverse events (withdrawals due to side effects) compared with placebo (low certainty).
1 finding from 1 review
- RR 1.86 [0.43, 8.1]3 studies · 241 participantsLow
Any cold therapy vs no cold therapy following total knee replacement
Withdrawals due to adverse events · people undergoing total knee replacement
It is very uncertain whether any cold therapy changes withdrawals due to adverse events compared with no cold therapy following total knee replacement (very low certainty).
1 finding from 1 review
- RR 2.71 [0.42, 17.38]19 studies · 1347 participantsVery low
Spinal cord stimulation vs placebo
Withdrawals due to adverse events · adults with low back pain
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsVery low
Anti‐TNF discontinuation vs anti‐TNF continuation
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.46 [0.75, 2.84]4 studies · 1116 participantsModerate
Anti‐TNF dose reduction vs anti‐TNF continuation
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyRR 1.07 [0.51, 2.24]3 studies · 937 participantsLow
Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation
Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
The review found no eligible studies for this question.
1 finding from 1 review
- Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.41 [0.81, 2.47]Studies not reportedLow
High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
- RR 0.89 [0.06, 13.08]3 studies · 104 participantsVery low
Risedronate 5 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes onlyRR 0.67 [0.38, 1.18]Studies not reportedLow
High‐dose vs low‐dose colchicine
Withdrawals due to adverse events · acute gout
1 finding from 1 review
- no estimate extracted1 study · 126 participantsGRADE not reported
Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
- Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 102 participantsVery low
Oral viscous budesonide vs swallowed fluticasone
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
- RR 0.98 [0.42, 2.32]1 study · 129 participantsLow
All doses of cerivastatin vs placebo
Withdrawals due to adverse events · participants with normal or abnormal lipid profiles
It is very uncertain whether all doses of cerivastatin changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.09 [0.68, 1.74]11 studies · 6570 participantsVery low
Six‐food elimination diet vs swallowed fluticasone compared to swallowed budesonide compared to oral viscous budesonide
Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Naftopidil vs Eviprostat (phytotherapy)
Withdrawals due to adverse events
It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).
1 finding from 1 review
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 49 participantsVery low
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
- High‐intensity versus low‐intensity physical activity or exercise in people with hip or knee osteoarthritis 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found